| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_883ef14066c153ff611ef557b6c22f71 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-07 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 |
| filingDate |
2011-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2da3e3d348204c8f96c9f943618d4eda
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f530f4c15f2363e8af030fdc331e8ffe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4510e480b6ef7453d2a8451a59dd1989
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8c707657f921401fab36add0c7db194 |
| publicationDate |
2018-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3290423-A1 |
| titleOfInvention |
Optically active 2-hydroxy tetrahydrothienopyridine derivatives, preparation method and use in manufacture of medicament thereof |
| abstract |
(S)-methyl 2 -( 2 -acetoxy-6, 7 -dihydrothieno[ 3 ,2-c]pyridin- 5 ( 4 H)-yl)-2-(2-chlorophenyl)-acetate and pharmaceutically acceptable salts, preparation method and use in the manufacture of a medicament thereof are disclosed. The pharmacodynamic experiment results show that the present compound is useful for inhibiting platelet aggregation. The pharmacokinetic experiment results show that the present compound can be converted in vivo into pharmacologically active metabolites and is therefore useful for inhibiting platelet aggregation. Therefore, the present compound is useful for the manufacture of a medicament for preventing or treating thrombosis and embolism related diseases. |
| priorityDate |
2010-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |